Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
July 2014

Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.

A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.

Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.

In Brief
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response

Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.